CONSTELLATION Trademark

Trademark Overview

On Monday, April 23, 2018, a trademark application was filed for CONSTELLATION with the United States Patent and Trademark Office. The USPTO has given the CONSTELLATION trademark a serial number of 87888540. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Tuesday, November 5, 2024. This trademark is owned by Constellation Pharmaceuticals, Inc.. The CONSTELLATION trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of cancer, inflammatory, and fibrotic disorders; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations for the treatment of lymphomia, solid cancers, blood disease, myelofibrosis, Alzheimer's disease, arthritis, Sjogren's syndrome, autoimmune hepatitis, systemic lupus erythematosus, venus thromboembolism (VTE), cancer associated thrombosis (CAT), renal autoimmune disease, pulmonary sarcoidosis, severe atopic dermatitis, diabetes, asthma, chronic obstructive pulmonary disease (COPD)

Pharmaceutical research and development; Research and development in the fields of genetics, pharmaceuticals, cancer, epigenetics, and immune-oncology, all of the foregoing for the purposes of drug development; conducting early evaluations in the field of new pharmaceuticals; development of pharmaceutical preparations and medicines; pharmaceutical products development
constellation

General Information

Serial Number87888540
Word MarkCONSTELLATION
Filing DateMonday, April 23, 2018
Status733 - FOURTH EXTENSION - GRANTED
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 13, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of cancer, inflammatory, and fibrotic disorders; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations for the treatment of lymphomia, solid cancers, blood disease, myelofibrosis, Alzheimer's disease, arthritis, Sjogren's syndrome, autoimmune hepatitis, systemic lupus erythematosus, venus thromboembolism (VTE), cancer associated thrombosis (CAT), renal autoimmune disease, pulmonary sarcoidosis, severe atopic dermatitis, diabetes, asthma, chronic obstructive pulmonary disease (COPD)
Goods and ServicesPharmaceutical research and development; Research and development in the fields of genetics, pharmaceuticals, cancer, epigenetics, and immune-oncology, all of the foregoing for the purposes of drug development; conducting early evaluations in the field of new pharmaceuticals; development of pharmaceutical preparations and medicines; pharmaceutical products development

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 2, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, May 2, 2018
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameConstellation Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameConstellation Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Thursday, April 26, 2018NEW APPLICATION ENTERED
Wednesday, May 2, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 13, 2018ASSIGNED TO EXAMINER
Monday, August 13, 2018SUSPENSION LETTER WRITTEN
Monday, August 13, 2018LETTER OF SUSPENSION E-MAILED
Monday, August 13, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, February 13, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, September 9, 2019NON-FINAL ACTION WRITTEN
Monday, September 9, 2019NON-FINAL ACTION E-MAILED
Monday, September 9, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 9, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 9, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 10, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 31, 2020FINAL REFUSAL WRITTEN
Tuesday, March 31, 2020FINAL REFUSAL E-MAILED
Tuesday, March 31, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, September 30, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, September 30, 2020EXPARTE APPEAL RECEIVED AT TTAB
Wednesday, September 30, 2020JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, September 30, 2020EX PARTE APPEAL-INSTITUTED
Tuesday, October 6, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, October 6, 2020SUSPENSION LETTER WRITTEN
Tuesday, October 6, 2020LETTER OF SUSPENSION E-MAILED
Friday, May 20, 2022SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Tuesday, July 5, 2022ACTION CONTINUING FINAL - COMPLETED
Wednesday, April 7, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, October 12, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, June 15, 2022SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Tuesday, July 5, 2022ACTION DENYING REQ FOR RECON E-MAILED
Tuesday, July 5, 2022NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Tuesday, August 2, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, August 3, 2022ASSIGNED TO LIE
Wednesday, August 3, 2022DATA MODIFICATION COMPLETED
Wednesday, August 10, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, August 10, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, August 10, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, August 10, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, August 10, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 24, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 13, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 8, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, May 8, 2023SOU TEAS EXTENSION RECEIVED
Monday, May 8, 2023SOU EXTENSION 1 FILED
Tuesday, September 13, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, October 12, 2022EXPARTE APPEAL TERMINATED
Monday, May 8, 2023SOU EXTENSION 1 GRANTED
Wednesday, May 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 7, 2023SOU TEAS EXTENSION RECEIVED
Thursday, November 9, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 6, 2024SOU EXTENSION 3 GRANTED
Tuesday, November 7, 2023SOU EXTENSION 2 FILED
Tuesday, November 7, 2023SOU EXTENSION 2 GRANTED
Monday, May 6, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 5, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, November 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 5, 2024SOU EXTENSION 4 GRANTED
Tuesday, November 5, 2024SOU EXTENSION 4 FILED
Monday, May 6, 2024SOU EXTENSION 3 FILED

Related Keywords

constellation pharmaceutical preparations development disease treatment cancer research epigenetic autoimmune pharmaceuticals